Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eflornithine/sulindac - Cancer Prevention Pharmaceuticals

Next Previous
Drug Profile

Eflornithine/sulindac - Cancer Prevention Pharmaceuticals

Alternative Names: CPP-1X/sul; CPP-1X/sulindac; CPP1-x/sulindac; Sulindac/CPP-1X; Sulindac/eflornithine; TP 09

Latest Information Update: 04 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Arizona; University of California at Irvine
  • Developer Cancer Prevention Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Basic amino acids; Diamino amino acids; Indenes; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Ornithine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Familial adenomatous polyposis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer; Familial adenomatous polyposis
  • Preclinical Pancreatic cancer

Most Recent Events

  • 04 Dec 2018 Preclinical trials in Pancreatic cancer in USA (PO), before December 2018 (Cancer Prevention Pharmaceuticals pipeline, December 2018)
  • 04 Dec 2018 Cancer Prevention Pharmaceuticals plans a phase II/III trial for Pancreatic Cancer (Cancer Prevention Pharmaceuticals pipeline, December 2018)
  • 04 Dec 2018 Cancer Prevention Pharmaceuticals plans a paediatric phase II/III trial for Familial Adenomatous Polyposis in EU (Cancer Prevention Pharmaceuticals pipeline, December 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top